Reblozyl (Luspatercept) 25 mg, Brystol-Mayers Luspatercept is indicated for the treatment of: Anemia in adults with beta thalassemia who require regular red blood cell transfusions. All Europe shipping 6-7 days, +380996042415

Indication

Luspatercept is indicated for the treatment of:

Anemia in adults with beta thalassemia who require regular red blood cell transfusions.6

Anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions.7

Anemia failing an erythropoiesis stimulating agent and requiring two or more RBC units over eight weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).7

for the treatment of transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS).